Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Tolerability of Cabotegravir and Rilpivirine Long-Acting Injections Following Intramuscular Administration in the Vastus Lateralis Muscle of Healthy Adult Participants

Next Previous
Trial Profile

A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Tolerability of Cabotegravir and Rilpivirine Long-Acting Injections Following Intramuscular Administration in the Vastus Lateralis Muscle of Healthy Adult Participants

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 24 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cabotegravir (Primary) ; Rilpivirine (Primary) ; Cabotegravir; Rilpivirine
  • Indications HIV infections
  • Focus Pharmacokinetics
  • Sponsors ViiV Healthcare

Most Recent Events

  • 01 Dec 2023 Results (n=15) describing the PK profiles of CAB LA and RPV LA following single IM injections of each to the lateral thigh muscle in healthy adult participants, published in the Antimicrobial Agents and Chemotherapy
  • 02 Aug 2022 Results assessing the pharmacokinetics and tolerability of cabotegravir and rilpivirine, intramuscular injections to the lateral thigh muscles of healthy participants, presented at the 24th International AIDS Conference.
  • 14 Feb 2022 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top